At the dawn of the new millennium, we have seen a vigorous clinical response to the changing and challenging problems of otitis media, with a high prevalence, greater bacterial resistance, and even greater educational and occupational impact than previously realized. New medical and surgical treatments and a better understanding of host-disease factors, including genetic and molecular investigations, may emerge from this productive year’s work. This update summarizes the latest epidemiologic and basic science studies, new medications, management of multidrug resistance by changing indications for antibiotic use and dosing regimens, the new pneumococcal vaccine, and the role of laser myringotomy.
Division of Pediatric Otolaryngology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA, and the Dept. of Otorhinolaryngology–Head and Neck Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Correspondence to Ian N. Jacobs, MD, Division of Pediatric Otolaryngology, The Children’s Hospital of Philadelphia, Richard D. Wood Center, 1st Floor, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104-4399, USA; e-mail: firstname.lastname@example.org